179 related articles for article (PubMed ID: 27619476)
1. Retinal proteome changes following experimental branch retinal vein occlusion and intervention with ranibizumab.
Cehofski LJ; Kruse A; Bøgsted M; Magnusdottir SO; Stensballe A; Honoré B; Vorum H
Exp Eye Res; 2016 Nov; 152():49-56. PubMed ID: 27619476
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone intravitreal implant downregulates PDGFR-α and upregulates caveolin-1 in experimental branch retinal vein occlusion.
Cehofski LJ; Kruse A; Magnusdottir SO; Alsing AN; Nielsen JE; Kirkeby S; Honoré B; Vorum H
Exp Eye Res; 2018 Jun; 171():174-182. PubMed ID: 29505751
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion.
Cehofski LJ; Kruse A; Alsing AN; Nielsen JE; Pedersen S; Kirkeby S; Honoré B; Vorum H
Mol Vis; 2018; 24():759-766. PubMed ID: 30581282
[TBL] [Abstract][Full Text] [Related]
4. Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion.
Cehofski LJ; Kruse A; Alsing AN; Sejergaard BF; Nielsen JE; Schlosser A; Sorensen GL; Grauslund J; Honoré B; Vorum H
Molecules; 2022 May; 27(11):. PubMed ID: 35684299
[TBL] [Abstract][Full Text] [Related]
5. Proteins involved in focal adhesion signaling pathways are differentially regulated in experimental branch retinal vein occlusion.
Cehofski LJ; Kruse A; Kjærgaard B; Stensballe A; Honoré B; Vorum H
Exp Eye Res; 2015 Sep; 138():87-95. PubMed ID: 26086079
[TBL] [Abstract][Full Text] [Related]
6. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Ranibizumab and Aqueous Humor Factors/Cytokines in Major and Macular Branch Retinal Vein Occlusion.
Noma H; Mimura T; Yasuda K; Nakagawa H; Motohashi R; Kotake O; Shimura M
Ophthalmologica; 2016; 235(4):203-7. PubMed ID: 27003517
[TBL] [Abstract][Full Text] [Related]
8. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S
J Fr Ophtalmol; 2016 Dec; 39(10):816-821. PubMed ID: 27865689
[TBL] [Abstract][Full Text] [Related]
9. Cytokine Levels in Experimental Branch Retinal Vein Occlusion Treated With Either Bevacizumab or Triamcinolone Acetonide.
McAllister IL; Vijayasekaran S; McLenachan S; Bhikoo R; Chen FK; Zhang D; Kanagalingam E; Yu DY
Transl Vis Sci Technol; 2024 Jun; 13(6):13. PubMed ID: 38899953
[TBL] [Abstract][Full Text] [Related]
10. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion.
Sacu S; Pemp B; Weigert G; Matt G; Garhofer G; Pruente C; Schmetterer L; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3046-50. PubMed ID: 21051706
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
12. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
13. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
Chuang LH; Wu WC; Yeung L; Wang NK; Hwang YS; Chen KJ; Kuo JZ; Lai CC
Ophthalmic Res; 2011; 45(1):31-5. PubMed ID: 20714188
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
Lim JW
Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment.
Kaneda S; Miyazaki D; Sasaki S; Yakura K; Terasaka Y; Miyake K; Ikeda Y; Funakoshi T; Baba T; Yamasaki A; Inoue Y
Invest Ophthalmol Vis Sci; 2011 May; 52(6):2982-8. PubMed ID: 21273540
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Anatomical and Functional Outcomes in Patients with Ischemic Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
Chatziralli I; Theodossiadis G; Parikakis E; Mitropoulos PG; Theodossiadis P
Ophthalmic Res; 2017; 58(4):203-208. PubMed ID: 28427057
[TBL] [Abstract][Full Text] [Related]
18. Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.
Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
BMC Ophthalmol; 2017 Jun; 17(1):90. PubMed ID: 28610573
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice.
Brynskov T; Kemp H; Sørensen TL
Retina; 2014 Aug; 34(8):1637-43. PubMed ID: 24646663
[TBL] [Abstract][Full Text] [Related]
20. [Six Months Outcome in Patients with Macular Edema Due to Retinal Vein Occlusion Treated with Ranibizumab].
Sakanishi Y; Ouchi A; Ito R; Ebihara N
Nippon Ganka Gakkai Zasshi; 2016 Jan; 120(1):28-34. PubMed ID: 26950966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
